Challenges of sarcoidosis and its management

M Drent, ED Crouser, J Grunewald - New England Journal of …, 2021 - Mass Medical Soc
Sarcoidosis Sarcoidosis is a lung disease of unknown cause characterized by noncaseating
granulomas; the heart and nervous system may also be involved. It is often misdiagnosed; …

Sarcoidosis: Epidemiology and clinical insights

M Rossides, P Darlington, S Kullberg… - Journal of internal …, 2023 - Wiley Online Library
Sarcoidosis is characterized by noncaseating granulomas which form in almost any part of
the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in …

ERS clinical practice guidelines on treatment of sarcoidosis

RP Baughman, D Valeyre, P Korsten… - European …, 2021 - Eur Respiratory Soc
Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

W Damsky, A Wang, DJ Kim, BD Young, K Singh… - Nature …, 2022 - nature.com
Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

The role of diverse immune cells in sarcoidosis

H Zhang, U Costabel, H Dai - Frontiers in immunology, 2021 - frontiersin.org
Sarcoidosis is a systemic inflammatory disorder of unknown etiology characterized by tissue
infiltration with macrophages and lymphocytes and associated non-caseating granuloma …

International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab

F Paul, R Marignier, J Palace, G Arrambide… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Neuromyelitis optica spectrum disorder (NMOSD) is a rare
debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently …

Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease

CC Moor, JC Oppenheimer… - European …, 2021 - Eur Respiratory Soc
Introduction Early and accurate diagnosis of interstitial lung diseases (ILDs) remains a major
challenge. Better noninvasive diagnostic tools are much needed. We aimed to assess the …

High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)

S Dhooria, IS Sehgal, R Agarwal… - European …, 2023 - Eur Respiratory Soc
Background Current guidelines recommend 20–40 mg· day− 1 of oral prednisolone for
treating pulmonary sarcoidosis. Whether the higher dose (40 mg· day− 1) can improve …

Toward equitable open research: stakeholder co-created recommendations for research institutions, funders and researchers

NL Cole, S Reichmann… - Royal Society Open …, 2023 - royalsocietypublishing.org
Open Research aims to make research more accessible, transparent, reproducible, shared
and collaborative. Doing so is meant to democratize and diversify access to knowledge and …

[HTML][HTML] Pulmonary sarcoidosis: a comprehensive review: past to present

JA Belperio, MC Fishbein, F Abtin, J Channick… - Journal of …, 2023 - Elsevier
Sarcoidosis is a sterile non-necrotizing granulomatous disease without known causes that
can involve multiple organs with a predilection for the lung and thoracic lymph nodes …